Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 353 participants.

Also called NCT02330406

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 353 participants (enrolled count) (from the registry)
Sponsor
Institute for Clinical Effectiveness, Japan (from the registry)
Registry
  • NCT NCT02330406
Other papers using this trial's data
  • Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial Cardiovascular diabetology, 2019-11-16 DOI, PubMed 31733647, PMC6858725 In the PMC Open Access subset under CC BY.
  • Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial Scientific reports, 2019-06-12 DOI, PubMed 31189978, PMC6561974 PubMed links an erratum for this paper. Erratum: PMID 32080316 In the PMC Open Access subset under CC BY.
  • Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy Cardiovascular diabetology, 2020-06-15 DOI, PubMed 32539832, PMC7296623 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02330406. Randomized; double masking; primary purpose treatment. Start 2015-04 (actual); primary completion 2018-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial
Acronym
REASON
Condition
Dipeptidyl-Peptidase 4 Inhibitors
Condition
Glycosylated Hemoglobin
Condition
Diabetes Mellitus
Condition
Coronary Disease
Intervention (Drug)
Anagliptin
Intervention (Drug)
Sitagliptin
Lead sponsor
Institute for Clinical Effectiveness, Japan (class: other)

Record details

Record id
cardio:ct-nct02330406
Content hash
799da9da55cb83255b92cfc291d2abd1df6988a8193ee59f4a4c2ce66224ab27